Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia

References

• Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for acute lymphoblastic leukemia. Leukemia 2010;24:255–264.
   PubMed Web of Science ®Google Scholar
• Möricke A, Zimmermann M, Reiter A, et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–284.
   PubMed Web of Science ®Google Scholar
• Pui C, Carroll W, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551–565.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Schrappe M, Bernardo M, et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012;120:2807–2816.
   PubMed Web of Science ®Google Scholar
• O’Shea J, Gadina M, Schreiber R. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109(Suppl.):S121–S131.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea J. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273–287.
   PubMed Web of Science ®Google Scholar
• Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800–802.
   PubMed Web of Science ®Google Scholar
• Park SY, Saijo K, Takahashi T, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995;3:771–782.
   PubMed Web of Science ®Google Scholar
• Grossman WJ, Verbsky JW, Yang L, et al. Dysregulated myelopoiesis in mice lacking Jak3. Blood 1999;94:932–939.
   PubMedGoogle Scholar
• Rochman Y, Spolski R, Leonard W. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009;9:480–490.
   PubMed Web of Science ®Google Scholar
• Walters D, Mercher T, Gu T, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65–75.
   PubMed Web of Science ®Google Scholar
• Choi Y, Kaneda R, Wada T, et al. Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res 2007;31:203–209.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007;21:574–576.
   PubMed Web of Science ®Google Scholar
• Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008;112:4220–4226.
   PubMed Web of Science ®Google Scholar
• Sato T, Toki T, Kanezaki R, et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol 2008;141:681–688.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Harveyc R, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Nati Acad Sci USA 2009;106:9414–9418.
   PubMed Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875–878.
   PubMed Web of Science ®Google Scholar
• Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002;277:47954–47963.
   PubMed Web of Science ®Google Scholar
• Baas AF, Boudeau J, Sapkota GP, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 2003;22:3062–3072.
   PubMed Web of Science ®Google Scholar
• Zhang X, Gureasko J, Shen K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137–1149.
   PubMed Web of Science ®Google Scholar
• Argestinger LS, Kouadio JL, Steen H, et al. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 2004;24:4955–4967.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Onc 2009;1:5175–5181.
   Web of Science ®Google Scholar
• Falchi L, Kantarjian HM, Wang X, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013;88:1024–1029.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–1127.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of Tg101348, a selective Jak2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789–796.
   PubMed Web of Science ®Google Scholar